ADHD children can now be prescribed a video game, said FDA. It will help the children to deal with their ADHD symptoms, so the ADHD children can get better
The first video game which is the treatment for attention deficit hyperactivity disorder (ADHD) has been approved by the US Food and Drug Administration (FDA).
The video game, called EndeavorRx and approved this Monday, will be prescription only and aimed at ADHD children between the ages of eight and 12 with certain types of ADHD.
It will be used alongside other treatments like clinician-directed therapy, medication, and educational programs.
ADHD is a common neurodevelopmental disorder that is usually first diagnosed in children and it can be last to adulthood.
It’s about 4 million children aged six to 11 who are affected by ADHD, the symptoms of which include difficulty staying focused and paying attention and difficulty controlling behavior.
This is the first game-based therapy to be granted marketing authorization by the FDA for any condition, the agency said.
“The EndeavorRx device offers a non-drug option for improving symptoms associated with ADHD children and is an important example of the growing field of digital therapy and digital therapeutics,” Dr. Jeffrey Shuren, director of the FDA’s Center for Devices and Radiological Health, announced in a press release.
The game, which can be downloaded as an app onto a mobile device, was authorized for marketing after the FDA reviewed five clinical studies that included more than 600 children.
The agency noted that some negative effects were reported like frustration, headache, dizziness, emotional reaction, and aggression, but said there were no really serious adverse effects reported.
While playing the game, children control an avatar through a course dotted with obstacles, collecting targets to earn rewards and win the stage.
Akili, the company that created EndeavorRx, has said that children with FDA should interact with the game 30 minutes per day, five days a week over the course of a one-month treatment cycle.
A representative for Akili said that the game was shown to improve attention function in the target population. “We’re proud to make history today with FDA’s decision,” said Eddie Martucci, CEO of Akili, in a press release from the organization.